Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
| Autor: | |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2014 |
| País: | España |
| Institución: | Universidad de Navarra |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/36415 |
| Acceso en línea: | https://hdl.handle.net/10171/36415 |
| Access Level: | acceso abierto |
| Palabra clave: | Bortezomib Multiple myeloma Humans Antineoplastic agents |
| Sumario: | Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. |
|---|